TY - JOUR
T1 - Sorbitol Dehydrogenase and Other Liver Enzymes Before and After Five Days Remdesivir Therapy in Covid-19 Patients
AU - Wardhani, Puspa
AU - Kustiah,
AU - Fuadi, M. Robiul
AU - Indrasari, Yulia Nadar
AU - Riadini, Dwita
AU - Semedi, Bambang Pujo
N1 - Funding Information:
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article. This study was supported by Airlangga University through the Grant Faculty's Flagship Research 2022. The author(s) expresses their gratitude to the Journal of Medicinal and Chemical Science for approving this research and RSUD Dr. Soetomo as well as all participating patients and family members for their cooperation to conduct this research.
Publisher Copyright:
© 2023 by SPC (Sami Publishing Company).
PY - 2023
Y1 - 2023
N2 - The antiviral remdesivir has the potential to cause drug-induced liver injury in Covid-19 patients as seen in increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Sorbitol dehydrogenase (SDH) is a cytoplasmic liver enzyme and can increase in acute liver injury, so it has been proposed as an alternative biomarker in liver injury. This study aimed to analyze the differences in serum SDH levels and other liver enzymes before and after 5 days of remdesivir therapy in Covid-19 patients. This was a prospective observational cohort conducted at RSUD Dr. Soetomo Surabaya, East Java between September and November 2022. The samples included in this study were selected consecutively. The venous blood sample were collected twice from each patient of 34 Covid-19 patients with positive real-time polymerase, namely on the first day of admission before receiving remdesivir therapy and after the fifth day of remdesivir therapy. Venous blood samples are then processed to obtain serum which will be used to measure SDH levels using the sandwich Enzyme-linked immunosorbent assay (ELISA) method and liver enzyme with Alinity-c analyzer. There were 34 subjects, 18 males and 16 females with median ages 56 years old. The median of serum SDH before and after 5 days therapy, respectively, was 0.75 U/L (SD=1.88) and 0.85 U/L (SD=1.32). The median difference of AST, ALT, direct bilirubin, total bilirubin, alkaline phosphatase (ALP), and gamma-glutamil transferase (GGT), respectively, were -3.75 mg/dL, -2 mg/dL, 0.045 mg/dL, 0.05 mg/dL, -3.5 mg/dL, and -1 mg/dL.
AB - The antiviral remdesivir has the potential to cause drug-induced liver injury in Covid-19 patients as seen in increased alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Sorbitol dehydrogenase (SDH) is a cytoplasmic liver enzyme and can increase in acute liver injury, so it has been proposed as an alternative biomarker in liver injury. This study aimed to analyze the differences in serum SDH levels and other liver enzymes before and after 5 days of remdesivir therapy in Covid-19 patients. This was a prospective observational cohort conducted at RSUD Dr. Soetomo Surabaya, East Java between September and November 2022. The samples included in this study were selected consecutively. The venous blood sample were collected twice from each patient of 34 Covid-19 patients with positive real-time polymerase, namely on the first day of admission before receiving remdesivir therapy and after the fifth day of remdesivir therapy. Venous blood samples are then processed to obtain serum which will be used to measure SDH levels using the sandwich Enzyme-linked immunosorbent assay (ELISA) method and liver enzyme with Alinity-c analyzer. There were 34 subjects, 18 males and 16 females with median ages 56 years old. The median of serum SDH before and after 5 days therapy, respectively, was 0.75 U/L (SD=1.88) and 0.85 U/L (SD=1.32). The median difference of AST, ALT, direct bilirubin, total bilirubin, alkaline phosphatase (ALP), and gamma-glutamil transferase (GGT), respectively, were -3.75 mg/dL, -2 mg/dL, 0.045 mg/dL, 0.05 mg/dL, -3.5 mg/dL, and -1 mg/dL.
KW - Covid-19
KW - Liver injury
KW - Remdesivir
KW - Sorbitol dehydrogenase
UR - http://www.scopus.com/inward/record.url?scp=85165277210&partnerID=8YFLogxK
U2 - 10.26655/JMCHEMSCI.2023.10.21
DO - 10.26655/JMCHEMSCI.2023.10.21
M3 - Article
AN - SCOPUS:85165277210
SN - 2651-4702
VL - 6
SP - 2470
EP - 2479
JO - Journal of Medicinal and Chemical Sciences
JF - Journal of Medicinal and Chemical Sciences
IS - 10
ER -